Saturday, October 31, 2026

Bullish Momentum: Splunk Stock Soars 24% In 10 Sessions

ViaNews Editorial Team

September 7, 2023

Bullish Momentum: Splunk Stock Soars 24% In 10 Sessions

(VIANEWS) - Splunk (NASDAQ: SPLK) shares experienced an astounding 24.88% jump over ten sessions, from EUR99.93 on August 23 to EUR124.79 at 11:25 EST on Thursday. This rally marked five consecutive sessions of gains; however, broader market sentiment remained negative as the NASDAQ index fell 1.07% to EUR13,724.430 due to three consecutive sessions of losses; Splunk's last close stood at EUR124.56 which marked an 7.21% gain versus its 52-week high of EUR116.18

About Splunk

Splunk Inc. specializes in software and cloud services designed to deliver comprehensive security and observability platforms. Splunk's offerings include Splunk Security, which assists organizations in mitigating cyber risk and meeting compliance requirements, and Splunk Observability, which offers visibility across infrastructure, applications and digital customer experience. Splunk Inc. provides APIs, SDKs and other interfaces for third-party developers, partners, customers and integration actions that allow third-party developers, partners and customers to develop content like prebuilt data inputs, workflows, searches reports alerts dashboards custom dashboards integration actions. Splunk Inc offers adoption education customer support services as well as direct sales. Founded in 2003 and located in San Francisco California.

Yearly Analysis

Based on the available information, here is an investment outlook for Splunk stock: Yearly Top and Bottom ValueDimensiuni Splunk's stock is currently trading at EUR124.79, above its 52-week high of EUR116.18. This indicates that investors have a positive outlook on Splunk's performance and its future growth prospects; however, its current value may also be affected by other factors, including market trends or investor sentiment. Anticipated Sales GrowthAccording to available information, Splunk's sales growth is anticipated at 7.7% this year and 11.6% in 2019. This indicates revenue is expected to increase over the next two years which could be good news for investors; however, keep in mind that these projections are estimates only and may differ significantly. Splunk's Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) of 5.48 suggests it has a healthy profit margin. Investors could take comfort knowing this metric indicates profits being generated while also maintaining a healthy financial position; however, EBITDA alone should not be used as the sole criteria to evaluate company financial health; instead investors should take other metrics, including revenue growth, profit margins and cash flow into consideration when making such evaluations. Conclusion Based on the information presented, Splunk appears to be trading above its 52-week high and sales growth should increase over the next two years. Furthermore, EBITDA indicates a healthy financial position. Investors should always conduct independent research and due diligence before making investment decisions, taking into account factors like market trends, competitive landscape, company-specific risks and opportunities before making their own judgement.

Technical Analysis

Splunk Inc. shares have been on an overall downward trajectory since the beginning of 2018, currently trading at EUR113.02 compared with their 52-week high of EUR134.21. Despite this drop, Splunk remains significantly above both their 50-day moving average (EUR104.04) and 200-day moving average (EUR94.83). The stock's daily trading volume was 364,523, representing an 8.86% decrease from its daily average volume of 1,610,420. This drop indicates a potential lack of interest for this stock and could potentially contribute to its downward trajectory. Splunk has experienced average intraday variation over its past week, month, and quarter of 1.21%, 1.01% and 1.60%, respectively. Furthermore, its highest amplitude of average volatility over those timeframes was 1.21% for week one; 1.61% for month two; and 1.60% for quarter three. According to the stochastic oscillator, which measures overbought and oversold conditions, Splunk stock is currently considered oversold (=20), signalling potential reversals in its downward trend and providing investors with buying opportunities. Splunk's stock appears to be oversold and may rebound soon, however investors should exercise caution and perform further research prior to making any investment decisions.

Quarter Analysis

Investment Prospectus of Splunk Inc. (SPLK). Splunk Inc. (SPLK) is a premier provider of data analytics and security solutions, helping organizations gain insight from their data. Splunk's projected quarterly sales growth estimates is 0.5%; this marks a slowdown from prior quarters but growth estimates for this quarter still stand strong at 37.3% indicating strong company expansion. Splunk has experienced year-on-year quarterly revenue growth that is consistently positive, increasing by 14% over the last twelve trailing months and reaching 3.84B currently. This success can be attributed to Splunk's efforts in expanding customer reach and strengthening product offerings. Overall, Splunk appears to present investors with an optimistic investment outlook, boasting strong growth projections for this quarter and an established track record of revenue expansion. Investors should monitor sales growth in subsequent quarters to ensure the company stays on its growth path.

Equity Analysis

Investment Outlook Splunk's trailing twelve months EPS stands at EUR-0.09, which indicates negative earnings at present and may dissuade potential investors looking for profitability. It should be remembered, however, that EPS should only ever be considered one factor of measuring financial health and performance of any organization. Other considerations when analyzing Splunk's investment outlook should include revenue growth, market share, competitive positioning and management's ability to execute on its strategic plans. Furthermore, analysts' earnings estimates and target prices may provide further insight into Splunk's future prospects. Overall, potential investors in Splunk should conduct extensive research and analysis to ascertain if its negative EPS performance is temporary or long-term trend. Furthermore, it's also crucial to take other financial metrics and qualitative factors into consideration in making an informed investment decision.

More news about Splunk (SPLK).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com